600867.SHG Tonghua Dongbao Pharmaceutical Co Ltd
- Market cap
- CNY 15.7B
- P/E
- 28.6x
- P/B
- 2.20x
- ROE
- 9.9%
- Dividend yield
- 3.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600867.SHG undervalued?
Graham number600867.SHG trades 67.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tonghua Dongbao Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Tonghua Dongbao Pharmaceutical Co Ltd yet.
Tonghua Dongbao Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning cap…
Full company profileTonghua Dongbao Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tonghua Dongbao Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.04B | 2.55B | 2.69B | 2.78B | 2.89B | 3.27B | 2.78B | 3.08B | 2.01B | 2.95B | 3.29B |
| Gross Profit | 1.54B | 1.89B | 1.94B | 2.05B | 2.31B | 2.68B | 2.15B | 2.45B | 1.46B | 2.07B | 2.33B |
| Operating Income | 739M | 986M | 993M | 968M | 1.18B | 1.55B | 1.83B | 1.37B | 168M | 603M | 850M |
| EBITDA | 964M | 1.16B | 1.16B | 1.13B | 1.27B | 1.68B | 1.98B | 1.56B | 58.1M | 1.77B | 838M |
| Net Income | 641M | 837M | 839M | 811M | 930M | 1.31B | 1.58B | 1.17B | -42.7M | 1.22B | 701M |
| EPS | 0.32 | 0.41 | 0.41 | 0.40 | 0.46 | 0.64 | 0.79 | 0.59 | -0.02 | 0.62 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 4.68B | 4.75B | 5.46B | 5.35B | 5.80B | 6.52B | 6.75B | 7.77B | 7.38B | 7.91B | 8.07B |
| Total Liabilities | 730M | 215M | 729M | 341M | 244M | 300M | 201M | 555M | 978M | 799M | 1.01B |
| Shareholders' Equity | 3.94B | 4.53B | 4.72B | 5.00B | 5.55B | 6.21B | 6.54B | 7.21B | 6.38B | 7.10B | 7.09B |
| Cash & Short-term Investments | 236M | 336M | 356M | 368M | 744M | 902M | 847M | 1.16B | 642M | 1.43B | 1.22B |
| Total Debt | 490M | 5.27M | 450M | 125M | 2.65M | 2.65M | 2.65M | 150M | 697M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 726M | 961M | 877M | 1.15B | 1.19B | 1.13B | 863M | 862M | 460M | 689M | - |
| Capital Expenditure | 412M | 185M | 773M | 293M | 480M | 601M | 492M | 348M | 569M | 518M | 388M |
| Free Cash Flow | 314M | 776M | 104M | 859M | 713M | 534M | 371M | 513M | -109M | 172M | 676M |
| Ratios | |||||||||||
| ROE | 16.3% | 18.5% | 17.8% | 16.2% | 16.7% | 21.1% | 24.2% | 16.2% | -0.7% | 17.2% | 9.9% |
| ROA | 13.7% | 17.6% | 15.3% | 15.2% | 16.0% | 20.1% | 23.4% | 15.0% | -0.6% | 15.4% | 8.7% |
| Net Profit Margin | 31.4% | 32.9% | 31.1% | 29.2% | 32.2% | 40.0% | 56.9% | 38.0% | -2.1% | 41.4% | 21.3% |
| Debt to Equity | 0.12x | 0.00x | 0.10x | 0.02x | 0.00x | 0.00x | 0.00x | 0.02x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tonghua Dongbao Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.22%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 41.4%
- Ex-dividend date
- Jun 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 505M | 0.26 | 41.4% |
| 2024 | CNY 495M | 0.23 | - |
| 2023 | CNY 496M | 0.25 | 42.5% |
| 2022 | CNY 1.10B | 0.55 | 69.3% |
| 2021 | CNY 425M | 0.21 | 32.5% |
| 2020 | CNY 404M | 0.20 | 43.4% |
| 2019 | CNY 407M | 0.20 | 50.1% |
| 2018 | CNY 356M | 0.17 | 42.4% |
| 2017 | CNY 300M | 0.15 | 35.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on May 25, 2018.
Who owns Tonghua Dongbao Pharmaceutical Co Ltd
- Insiders 33.11%
- Institutions 15.35%
- Public & others 51.54%
- Shares outstanding 1.96B
- Free float 1.02B
Tonghua Dongbao Pharmaceutical Co Ltd company profile
- Company name
- Tonghua Dongbao Pharmaceutical Co Ltd
- Ticker
- 600867.SHG
- ISIN
- CNE000000H87
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 30, 1994
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,354
- Fiscal year end
- December
- Address
- Dongbao New Village, Tonghua, China, 134123
- Phone
- 86 43 5508 8008
- Website
- thdb.com
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenamine maleate granules; zhennaoning capsules; compound methionine and choline bitartrate tablets; and compound kushen changyankang tablets. It also provides insulin pens and pen needles; and the Chronic Disease Management Platform, which is a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, the company offers oral anti-diabetic hypoglycemic drugs, such as sitagliptin phosphate, sitagliptin phosphate/metformin hydrochloride, repaglinide, and engagliflozin tablets. Further, it engages in the manufacture, sale, and servicing of plastic building materials and products; technology development of biological products and natural medicines; leasing of workshops; real estate development and sales; second-hand housing transactions; provision of biopharmaceuticals; medical research and experimental development; pharmaceutical retail and wholesale; technical services, technology development, and technical consulting; operation of medical devices and food products; import and export of goods and technologies; internet sales; and health and consulting services. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.
Tonghua Dongbao Pharmaceutical Co Ltd management
3- Mr. Jiahong LiChairman, President & Secretary · born 1988
- Mr. Guodong ZhangDeputy GM & Director · born 1976
- Mr. Wenhai ZhangVP & Director · born 1974